FLU Vaccine Study

During the 2021-2022 influenza (flu) season, current seasonal flu vaccines were only 36% effective. A messenger RNA (mRNA) vaccine may offer broader protection by responding to changes in seasonal flu strains more quickly and creating stronger immune responses. This trial will look at the safety and immune response of an mRNA-based investigational vaccine aimed at preventing seasonal flu in adults.